Akash Tewari, an analyst from Jefferies, maintained the Buy rating on Argenx Se (ARGX – Research Report). The associated price target remains the same with $772.00.
Akash Tewari has given his Buy rating due to a combination of factors surrounding Argenx Se’s recent developments. The FDA’s approval of Vyvgart Hytrulo’s pre-filled syringe for at-home self-injection is a significant milestone, offering a more convenient option for patients without the need for healthcare professional supervision. This new delivery method not only reduces injection time but also simplifies the process, potentially increasing patient adherence and expanding the drug’s market reach.
Furthermore, management anticipates that the price increase and expected growth in gross-to-net (GTN) will be balanced by volume growth, particularly as the product moves through Medicare Part D. The company’s strategic plans, including the future launch of an auto-injector, and its strong position in the gMG and CIDP markets, contribute to the positive outlook. These elements, combined with the company’s resilience against market fluctuations and tariffs due to its US manufacturing base, make Argenx Se a compelling investment opportunity.
Tewari covers the Healthcare sector, focusing on stocks such as Pfizer, Eli Lilly & Co, and Merck & Company. According to TipRanks, Tewari has an average return of 2.1% and a 37.41% success rate on recommended stocks.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $720.00 price target.